Accessibility Menu
Dice Therapeutics logo

Dice Therapeutics(NASDAQ) DICE

This security has been delisted. This page is retained for historical reference.

Dice Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 47.552023-08-08
Dice Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.72%USD 47.212023-08-01
1 month+2.48%USD 46.402023-07-07
3 month+25.69%USD 37.832023-05-10
Year to date+52.4%USD 31.202022-12-30
1 year+140.88%USD 19.742022-08-08
Since inception+28.9%USD 36.892021-09-15

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

DICE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

56.07%

Return on Capital

N/A

Return on Assets

-13.75%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$118.69M

EBITDA

-$98.70M

Operating Cash Flow

-$84.23M

Capital Expenditure

-$2.99M

Free Cash Flow

-$87.22M

Cash & ST Invst.

$528.38M

Total Debt

$12.58M

Dice Therapeutics Performance Analysis

Dice Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,125,000N/A
20222022-12-31USD 0N/A
Dice Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30N/A
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Dice Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.28N/A
20222022-12-31USD -2.1366.2%
Dice Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-308.6%
Q42022-12-315.7%
Q12023-03-3116.0%
Q22023-06-30-76.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

71

N/A

Net Income

-$34.82M

-60.3%

EBITDA

-$34.13M

-66.0%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$528.38M

+87.2%

Total Debt

$12.58M

-9.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$11.05M

-12.2%

Short Term Debt

$1.53M

+16.2%

Return on Assets

-13.75%

N/A

Return on Invested Capital

-15.24%

N/A

Free Cash Flow

-$30.41M

-70.5%

Operating Cash Flow

-$28.58M

-68.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CALTCalliditas Therapeutics AB (publ)
$40.00-0.10%
LBPHLongboard Pharmaceuticals, Inc.
$59.98N/A
PRVBProvention Bio, Inc.
$24.98+0.00%
BLUBELLUS Health Inc.
$14.75+0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.